The use of tocilizumab to treat recurrent thyroid eye disease previously treated with teprotumumab

The use of biologics in the treatment of corticosteroid-resistant thyroid eye disease has increased in popularity over the last several years. Here, we describe a patient with progression of symptoms despite multiple courses of corticosteroids, orbital decompression, and teprotumumab. The patient was successfully treated with tocilizumab and remains clinically stable 18 months status post treatment.